Inventiva

89 articles about Inventiva

• Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

  8/31/2023

  Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced an approximately €35.7 million financing.

• Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

  7/27/2023

  Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.

• Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

  7/27/2023

  Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.

• Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

  6/24/2023

  Inventiva announced that the abstract “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated With Responses in Adiponectin Levels” has been selected for poster presentation during the American Diabetes Association’s 83rd Scientific Sessions taking place on June 23-26, 202 in San Diego, United States.

• Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

  6/13/2023

  Inventiva (Euronext Paris and Nasdaq: IVA) today announced positive topline results of the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus (T2D).

• Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  

  6/8/2023

  Inventiva and Echosens announce their collaboration in raising awareness about NASH and increase access to screening for patients at risk of developing NASH.

• Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

  6/7/2023

  Inventiva announced that five abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2023 hosted by the European Association for the Study of the Liver on June 21-24, 2023 in Vienna, Austria.

• Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023

  5/26/2023

  Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases with unmet medical need, announced the results of the votes of its Combined Shareholders’ Meeting.

• Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

  5/25/2023

  Inventiva and Sino Biopharm, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., announce that CTTQ received Investigational New Drug approval from the Chinese National Medical Products Administration on May 22nd 2023, and can now initiate the clinical development of Inventiva’s lead compound lanifibranor in mainland China.

• Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

  5/16/2023

  Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today reported financial information for the first quarter of 2023, including its cash, cash equivalents and revenues, and provided a corporate update.

• Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F

  3/30/2023

  Inventiva announced that it had filed its 2022 Universal Registration Document for the year ended December 31, 2022, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” and its 2022 Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S.

• Inventiva reports its 2022 full-year results

  3/29/2023

  Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, reported its full-year results for 2022.

• Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

  3/23/2023

  Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023.

• Inventiva reports preliminary financial results for Full-Year 2022¹

  2/14/2023

  Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022.

• Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

  2/14/2023

  Inventiva reported certain preliminary financial results as of and for the year ended December 31, 2022.

• Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

  12/12/2022

  Inventiva announced the receipt of the €25 million payment under the first tranche of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date of December 2026.

• Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

  11/28/2022

  Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage.

• Inventiva reports 2022 Third Quarter Financial Information¹

  11/10/2022

  Inventiva reported its cash position as of September 30, 2022 and its revenues for the first nine months of 2022.

• Inventiva provides an update on the development of cedirogant by AbbVie

  10/31/2022

  Inventiva announced that AbbVie communicated during their third-quarter financial results on Friday October 28th, that they decided to stop the development of cedirogant, an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study.

• Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

  10/21/2022

  Inventiva (Euronext Paris and Nasdaq: IVA) today announced that a scientific abstract has been selected for poster presentation at the upcoming The Liver Meeting® 2022 hosted by the American Association for the Study of Liver Diseases on November 4-8, 2022 in Washington, DC.